Mustafa Rawaf, DO
Psychiatry · Las Vegas, NVNPI 1114241973
Payments from drug & device makers
Across 895 payments — averaging $5723.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2.3M
- E.r. Squibb & Sons, L.L.C.$690K
- Axsome Therapeutics, Inc.$613K
- Sage Therapeutics, LLC$419K
- Bioxcel Therapeutics, Inc.$216K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$197K
- plus $647K from 18 others
Across 13 payments — averaging $390.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Indivior Inc.$2K
What the payments were for
- Consulting fees$3,0762%
- Speaking & faculty fees$143,39786%
- Travel & lodging$12,9368%
- Food & beverage$6,4424%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 363 | $2,340,579 |
| E.r. Squibb & Sons, L.L.C. | 13 | $690,461 |
| Axsome Therapeutics, Inc. | 38 | $612,930 |
| Sage Therapeutics, LLC | 77 | $418,649 |
| Bioxcel Therapeutics, Inc. | 15 | $215,566 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 15 | $197,424 |
| Otsuka America Pharmaceutical, Inc. | 180 | $156,651 |
| Supernus Pharmaceuticals, Inc. | 16 | $155,917 |
| Boehringer Ingelheim | 7 | $88,852 |
| Sumitomo Pharma America, Inc. | 46 | $63,856 |
| Indivior Inc. | 18 | $49,465 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $36,426 |
| Neurocrine Biosciences, Inc. | 30 | $29,621 |
| Boehringer Ingelheim International GmbH | 23 | $24,410 |
| F. Hoffmann-la Roche AG | 6 | $14,400 |
| Vanda Pharmaceuticals Inc. | 1 | $9,079 |
| Biohaven Pharmaceuticals, Inc. | 3 | $8,600 |
| Sunovion Pharmaceuticals Inc. | 19 | $6,900 |
| Alkermes, Inc. | 8 | $2,423 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $272 |
| Tris Pharma Inc | 1 | $107 |
| BD | 1 | $103 |
| Braeburn Inc. | 1 | $95 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$100,469
- REXULTI$55,604
- ABILIFY ASIMTUFII$46,888
- LATUDA$6,654
- CAPLYTA$258
- LONHALA MAGNAIR$123
- Dyanavel XR$107
- Pyxis$103
How this compares
$5,122,799 in reported general payments places this provider in the 95th percentile of 243 psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $546 |
| Olanzapine | 13 | $148 |
| Quetiapine Fumarate | 21 | $139 |
| Gabapentin | 16 | $92 |
| Divalproex Sodium | 11 | $88 |
| Trazodone Hcl | 21 | $45 |
| Pantoprazole Sodium | 11 | $34 |
| Amlodipine Besylate | 11 | $23 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Las Vegas
- Jelena KunovacLas Vegas$12.4M
- Aaron RitterLas Vegas$2.7M
- John AnooshianLas Vegas$836K
- Sam ZandLas Vegas$410K
- Dylan WintLas Vegas$272K
- Akindele KoladeLas Vegas$79K
- Mujeeb ShadLas Vegas$55K
- Dax WolfordLas Vegas$29K
- Faisal SubaLas Vegas$18K
- Ejine OkoroaforLas Vegas$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.